Ex vivo COL7A1 editing via CRISPR/Cas9 in recessive dystrophic epidermolysis bullosa
Hainzl, S; Peking, P; Kocher, T; Murauer, E; Larcher, F; Duarte, B; Steiner, M; Bauer, J; Reichelt, J; Koller, U J INVEST DERMATOL. 2017; 137(5): S92-S92.
Enhanced genome editing using split Staphylococcus aureus Cas9 delivered in self-complementary AAV vectors
Liemberger, B; Arzt, C; Hainzl, S; Wally, V; Kocher, T; Hofbauer, JP; Murauer, EM; Bauer, JW; Reichelt, J; Koller, U HUM GENE THER. 2017; 28(12): A63-A63.
Highly efficient and safe CRISPR/Cas9n double nicking-mediated KRT14 repair in epidermolysis bullosa simplex keratinocytes
Kocher, T; Peking, P; Klausegger, A; Murauer, EM; Hofbauer, JP; Wally, V; Lettner, T; Hainzl, S; Ablinger, M; Bauer, JW; Reichelt, J; Koller, U HUM GENE THER. 2017; 28(12): A57-A57.
SUCCESSFUL LONG-TERM MAINTENANCE OF PV PATIENTS WITH A MONTHLY SCHEDULE OF ROPEGINTERFERON ALFA-2B-AN UPDATE FROM THE PEGINVERA STUDY
Buxhofer-Ausch, V; Grohmann-Izay, B; Thaler, J; Schloegl, E; Gastl, G; Wolf, D; Kralovics, R; Gisslinger, B; Ban, S; Egle, A; Melchardt, T; Burgstaller, S; Willenbacher, E; Schalling, M; Krauth, MT; Greil, R; Zoerer, M; Kadlecova, P; Klade, C; Gisslinger, H HAEMATOLOGICA. 2017; 102: 284-284.
ALL ORAL COMBINATION OF IXAZOMIB PLUS THALIDOMIDE AND DEXAMETHASONE FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA: INTERIM DATA OF AN ONGOING PHASE II TRIAL
Ludwig, H; Poenisch, W; Knop, S; Schreder, M; Lechner, D; Hajek, R; Gunsilius, E; Fridrik, M; Petzer, A; Weisel, K; Rauch, E; Greil, R; Zojer, N HAEMATOLOGICA. 2017; 102: 110-110.
T-cell immune response: a prognostic factor for pathological_x000D_ regression in previously adjuvant treated colorectal cancer liver metastasis
Klieser, E; Krenn, P; Urbas, R; Primavesi, F, Stättner, S; Sotlar, K; Neureiter, D; Hartmann, TN Der Pathologe. 2017; 38(Supp. 1):S132-S132.-101. Jahrestagung der Deutschen Gesellschaft für Pathologie e. V.; 22.-24.06.2017; Erlangen.
Low expression of miR-20a-5p predicts benefit to bevacizumab in metastatic breast cancer patients treated within the TANIA trial.
Gampenrieder, SP; Rinnerthaler, G; Hackl, H; Steiner, M; Monzo Fuentes, C; Hufnagl, C; Hauser-Kronberger, C; Egle, A; Greil, R; Low expression of miR-20a-5p predicts benefit to bevacizumab in metastatic breast cancer patients treated within the TANIA trial. 2017; 28(suppl_5):v22-v42.-ESMO 2017 Congress; 08.-12.09.2017; Madrid.
CLL cells residing in spleen and bone marrow microenvironments differ in their CD44 variant usage for migration and proliferation
Gutjahr, JC; Szenes, E; Tschech, L; Schlederer, M; Roos, S; Asslaber, D; Girbl, T; Greil, R; Alon, R; Kenner, L; Orian-Rousseau, V; Hartmann, TN Leukemia & Lymphoma. 2017; 58(sup1):1-240.-iwCLL; 12.05-15.05.2017; New York.
CLL cells residing in spleen and bone marrow microenvironments differ in their CD44 variant usage for migration and proliferation
Roos, S; Schlederer, M; Hartmann, T; Gutjahr, JC; Szenes, E; Tschech, L; Girbl, T; Greil, R; Kenner, L; Orian-Rousseau, V; Ronen, A LEUKEMIA LYMPHOMA. 2017; 58: 41-42.
Uveitis – Differentialdiagnose und Therapie
Psenak, O; Uveitis – Interdisziplinär; 19.04.2017; Salzburg. 2017.
